Loading
institutionsInstitution
Winship Cancer Institute of Emory University
Winship is Georgia's only NCI comprehensive cancer centre; its myeloma programme under Sagar Lonial shaped daratumumab development, Suresh Ramalingam led the FLAURA trial that made osimertinib first-line for EGFR-mutant lung cancer, and it runs one of the South's largest phase 1 units.
Overview
Founded in 1937 and NCI-designated in 2009, Winship achieved comprehensive status in 2017 and is Georgia's only NCI comprehensive centre. Sagar Lonial's myeloma programme has been central to daratumumab and other anti-CD38 and immunomodulatory drug development; Suresh Ramalingam led the FLAURA trial that made osimertinib the first-line standard in EGFR-mutant lung cancer. Kevin Kalinsky led RxPONDER, which defined which node-positive, HR-positive breast cancer patients benefit from chemotherapy. Winship opened a dedicated cancer tower at Emory Midtown in 2023 and runs one of the South's largest phase 1 units.
Location
Atlanta, GA, US
Type
cancer center · Emory University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#81 · 43 points (0 Newsweek + 15 NCI + 28 from 14 linked objects) · ranking
- Multiple myeloma
- EGFR-mutant lung cancer (FLAURA)
- Breast cancer (RxPONDER)
- Phase 1 unit
Kevin Kalinsky
Director, Glenn Family Breast Center, Winship Cancer Institute of Emory University
Breast cancerGenomic assaysNode-positive disease
Led RxPONDER, which showed postmenopausal women with 1-3 positive nodes and low recurrence scores do not need chemotherapy.
Robert W. Woodruff
Coca-Cola president whose 1937 gift founded Emory's Winship Cancer Institute in memory of his mother
Cancer centre foundingSouthern US cancer care
After his mother Emily Winship Woodruff died of cancer in 1937, he gave Emory University the gift that founded the Winship Clinic; his foundation's $400 million gift in 2018 is building Winship's new Midtown Atlanta home.
Sagar Lonial
Chair of Hematology and Medical Oncology and Chief Medical Officer, Winship Cancer Institute of Emory University
Multiple myelomaAntibody-drug conjugatesDaratumumab
Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma.
Suresh S. Ramalingam
Executive Director
Lung cancerThoracic medical oncologyTargeted therapy
Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.
Deborah Watkins Bruner
Senior Vice President for Research, Emory University; NRG Oncology Vice Chair
Patient-reported outcomesRadiation oncology nursingTrial design
Nurse scientist who put patient-reported outcomes into cooperative group radiation trials.
Similar pages
- PersonKathy S. Albain
Shares RxPONDER (SWOG S1007), Oncotype DX, SWOG Cancer Research Network, HR-positive / HER2-negative breast cancer.
- InstitutionThe University of Kansas Cancer Center
Shares SWOG Cancer Research Network, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH).
- InstitutionUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH), Multiple myeloma.
- PairingGene-expression assay → chemotherapy omission
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH), Multiple myeloma.
- TechnologyGene-expression prognostic assays
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
- TrialALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
Shares NRG Oncology, SWOG Cancer Research Network, Osimertinib, National Cancer Institute (NIH).
- TrialDRAMMATIC
Shares Daratumumab, SWOG Cancer Research Network, Multiple myeloma.
cancers
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-CD38)
Daratumumab · Darzalex / Darzalex Faspro (SC)
EstablishedGene-expression prognostic/predictive assay
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso